TORONTO, Dec. 17, 2020 /PRNewswire-PRWeb/ — Dentists can expect to be better than ever before in catching undiagnosed or overlooked conditions and identifying pathologies thanks to Denti.AI’s radiographic analysis, new clinical research shows.
The American Academy of Oral and Maxillofacial Radiology awarded the prestigious 2020 Albert G. Richards Graduate Student Research Award to a University of North Carolina Adams School of Dentistry graduate student who showed the artificial intelligence software often accurately identified pathoses missed by board-certified dental experts.
Manal Hamdan, DDS, conducted the study titled “Detecting Apical Radiolucencies Using Deep Learning Technology: A Pilot Study.” She concluded that Denti.AI’s technology had comparable or improved results, and the artificial intelligence tool has the potential to reduce provider fatigue and diagnostic errors. Her poster on the same research won first prize for the best scientific poster at the AAOMR annual session.
Dr. Don Tyndall, Professor of Oral and Maxillofacial Radiology at the Adams School of Dentistry stated, “Dr. Hamdan’s research is an excellent example of university and business collaboration utilizing experts in radiology, deep learning and statistical analysis to produce clinically relevant and potentially game changing results validating software that can elevate patient care.”
“Our team at Denti.AI is committed to being at the forefront of implementing artificial intelligence into clinical practices through rigorous academic validation and collaboration with leading academic institutions,” said Dmitry Tuzoff, founder and CEO of Denti.AI.
This is the second academic award the company’s product has received this year. The University of Louisville awarded first prize to a separate clinical study featuring Denti.AI’s technology.
“We are building technology to help support oral health providers by bringing clarity, standardization, quality assurance, efficiency, and trust to the dental marketplace,” said Eric Pulver, DDS, the Chief Dental Officer of Denti.AI.
With Denti.AI’s radiograph analysis, providers will catch more pathologies and help patients better understand the need for treatment to increase both quality of care and case acceptance. Denti.AI’s cloud-based software centralizes the clinical data into its analytics platform, which makes it easy to see business performance in relation to hard clinical data. Plus, its patent-pending auto-charting technology incorporates the radiographs directly into the clinical workflow which improves operational efficiency.
Thanks to the AI-powered medical imaging technology, dental practices gain profitability, speed and quality. With Denti.AI, it only takes several seconds to interpret a series of intraoral x-rays or a panoramic image and produce a complete dental chart. Based on the experience of professional radiologists who participated in the training of the algorithms, Denti.AI looks to find what the naked eye often cannot. You can see for yourself at Denti.AI.
Denti.AI (http://www.denti.ai) is a software company that leverages AI analysis of dental x-rays to detect key abnormalities, past dental treatments, and other relevant features to find problems earlier and improve productivity. Its cloud-based service is integrated with a range of practice management software and imaging equipment, automating the clinical workflow of dental support organizations across North America.
For more information, or to participate in a free trial, visit http://www.denti.ai
Reporters May Contact:
Jeff Durrbeck VP of Sales
jdurrbeck@denti.ai
Media Contact
JEFFREY DURRBECK, Denti.AI Technology Inc., +1 3036568690, jdurrbeck@denti.ai
SOURCE Denti.AI Technology Inc.
Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…